Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of two therapeutic schemes(abidol hydrochloride,abidol hydrochloride combined with interferon atomization)in the treatment of 2019-nCoV viral pneumonia, so as to provide reliable evidence-based medicine for the treatment of viral pneumonia caused by 2019-nCoV.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Abidol hydrochloride | Experimental | Standard symptomatic support therapy (SMT) plus abidol hydrochloride(0.2g, 3 times a day). |
|
| Abidol Hydrochloride combined with Interferon atomization | Experimental | Interferon(PegIFN-α-2b) atomization was added(45ug, add to sterile water 2ml, twice a day) on the basis of group I. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Abidol hydrochloride | Drug | 0.2g once, 3 times a day,two weeks |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of disease remission | A: For mild patients : fever, cough and other symptoms relieved with improved lung CT; B:For severe patients : fever, cough and other symptoms relieved with improved lung CT,SPO2> 93% or PaO2/FiO2> 300mmHg (1mmHg=0.133Kpa); | two weeks |
| Time for lung recovery | Compare the average time of lung imaging recovery after 2 weeks of treatment in each group. | two weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of no fever | two weeks | |
| Rate of respiratory symptom remission | two weeks | |
| Rate of lung imaging recovery |
Not provided
Inclusion Criteria:
1)2019-nCoV nucleic acid test was positive. 2)CT of the lung conformed to the manifestation of viral pneumonia.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Qing Ning, Professor | Contact | +8613971521450 | qning@vip.sina.com | |
| Meifang Han, Professor | Contact | +8613986093605 | mfhan@foxmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department and Institute of Infectious Disease | Recruiting | Wuhan | Hubei | 430030 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Abidol Hydrochloride combined with Interferon atomization |
| Drug |
Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks |
|
| two weeks |
| Rate of CRP,ES,Biochemical criterion (CK,ALT,Mb)recovery | two weeks |
| Rate of undetectable viral RNA | two weeks |